KML001 inhibits cell proliferation and invasion in pancreatic cancer cells through suppression of NF-κB and VEGF-C

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3469-3474

  Yang, Moon Hee ^a   Kim, Hyung Tae ^a   Lee, Kyu Taek ^a   Yang, Sera ^b   Lee, Jong Kyoon ^a   Lee, Kwang Hyuck ^a   Rhee, Jong Chul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Invasion; KML001; NF B; Pancreatic cancer; Proliferation; VEGF C.

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KML 001; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; VASCULOTROPIN C; ARSENITE SODIUM; ARSENOUS ACID DERIVATIVE; SODIUM DERIVATIVE; TRANSCRIPTION FACTOR RELA; VEGFC PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PANCREATIC CANCER CELL LINE; TUMOR INVASION; CELL GROWTH; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; INVASION; KML001; MALE; METABOLISM; NF-ΚB; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROLIFERATION; TUMOR CELL LINE; VEGF-C;

INVASION; KML001; NF-ΚB; PANCREATIC CANCER; PROLIFERATION; VEGF-C;

ARSENITES; CARCINOMA, PANCREATIC DUCTAL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; MALE; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; SODIUM COMPOUNDS; TRANSCRIPTION FACTOR RELA; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84906324102     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Wang YW, Wang SJ, Zhou YN, Pan SH and Sun B: Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol 138: 785-797, 2012.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
3. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861, 2007.
4. Shi S, Yao W, Xu J, Long J, Liu C and Yu X: Combinational therapy: New hope for pancreatic cancer? Cancer Lett 317: 127-135, 2012.
5. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ and Ajani JA: Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 107: 676-685, 2006.
6. Ricciardi S, Mey V, Nannizzi S, Pasqualetti G, Crea F, Del Tacca M and Danesi R: Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. Chemotherapy 56: 303-312, 2010.
7. Waxman S and Anderson KC: History of the development of arsenic derivatives in cancer therapy. Oncologist 6(Suppl 2): 3-10, 2001.
8. Tingting R, Wei G, Changliang P, Xinchang L and Yi Y: Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway. Cancer Biol Ther 10: 251-257, 2010.
9. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ and Chen Z: Arsenic trioxide, a therapeutic agent for APL. Oncogene 20: 7146-7153, 2001.
10. Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM and Zheng MH: Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med 4: 33-37, 1999.
11. Zhang TC, Cao EH, Li JF, Ma W and Qin JF: Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 35: 1258-1263, 1999.
12. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB and Goker E: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 6: 4957-4964, 2000.
13. Akao Y, Nakagawa Y and Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455: 59-62, 1999.
14. Phatak P, Dai F, Butler M, Nandakumar MP, Gutierrez PL, Edelman MJ, Hendriks H and Burger AM: KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Clin Cancer Res 14: 4593-4602, 2008.
15. Glienke W, Chow KU, Bauer N and Bergmann L: Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma 47: 1629-1638, 2006.
16. Ivanov VN, Zhou H and Hei TK: Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res 67: 5397-5407, 2007.
17. Aghdassi A, Phillips P, Dudeja V, Dhaulakhandi D, Sharif R, Dawra R, Lerch MM and Saluja A: Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res 67: 616-625, 2007.
18. Nam KN, Son MS, Park JH and Lee EH: Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-kappaB: neuroprotective implications. Neuropharmacology 55: 819-825, 2008.
19. Holcomb B, Yip-Schneider M and Schmidt CM: The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 36: 225-235, 2008.
20. Kim JW, Jang SM, Kim CH, An JH, Kang EJ and Choi KH: New molecular bridge between RelA/p65 and NF-kappaB target genes via histone acetyltransferase TIP60 cofactor. J Biol Chem 287: 7780-7791, 2012.
21. Zhao YC, Ni XJ, Li Y, Dai M, Yuan ZX, Zhu YY and Luo CY: Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients. World J Surg Oncol 10: 165, 2012.
22. Kumar B, Chile SA, Ray KB, Reddy GE, Addepalli MK, Kumar AS, Ramana V and Rajagopal V: VEGF-C differentially regulates VEGF-A expression in ocular and cancer cells; promotes angiogenesis via RhoA mediated pathway. Angiogenesis 14: 371-380, 2011.
23. Park SY, Kim JH, Lee YJ, Lee SJ and Kim Y: Surfactin suppresses TPA-induced breast cancer cell invasion through the inhibition of MMP-9 expression. Int J Oncol 42: 287-296, 2013.
24. Jeon BG, Kumar BM, Kang EJ, Maeng GH, Lee YM, Hah YS, Ock SA, Kwack DO, Park BW and Rho GJ: Differential cytotoxic effects of sodium meta-arsenite on human cancer cells, dental papilla stem cells and somatic cells correlate with telomeric properties and gene expression. Anticancer Res 31: 4315-4328, 2011.
25. Skrobot Vidacek N, Cukusic A, Ferenac Kis M, Ivankovic M, Jevtov I, Mrsic S and Rubelj I: Telomere dynamics and genome stability in the human pancreatic tumor cell line MIAPaCa-2. Cytogenet Genome Res 119: 60-67, 2007.
26. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H and Wirth T: NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Lett 295: 214-228, 2010.
27. Roussel RR and Barchowsky A: Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch Biochem Biophys 377: 204-212, 2000.
28. Park MJ, Lee JY, Kwak HJ, Park CM, Lee HC, Woo SH, Jin HO, Han CJ, An S, Lee SH, Chung HY, Park IC, Hong SI and Rhee CH: Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem 95: 955-969, 2005.
29. Chen Y, Jiang L, She F, Tang N, Wang X, Li X, Han S and Zhu J: Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism. Mol Cell Biochem 345: 77-89, 2010.
30. Duan L, Ye L, Zhao G, Wu Z, Jin C, Cai X and Li G: Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg 43: e58-63, 2013.
31. Zhang K, Chen D, Jiao X, Zhang S, Liu X, Cao J, Wu L and Wang D: Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. Lab Invest 91: 426-438, 2011.
32. Li CY, Yuan P, Lin SS, Song CF, Guan WY, Yuan L, Lai RB, Gao Y and Wang Y: Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumour Biol 34: 735-741, 2013.